The present invention is related to novel oral compositions comprising anirreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastricacid secretion inhibitor and one or more small carboxylic acid molecules asparietal cell activators in the gastric lumen. Unexpectedly, the compositionsof the present invention are capable of enhancing the anti-acid activity ofPPI in the stomach. The present invention further relates to a method of usingsuch compositions to reduce gastric acid secretion in a mammal.
